Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in Phase 2 clinical trial for the treatment of patients with hyperkalemia; and RDX020, a small molecule program for the treatment of metabolic acidosis. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Fremont, California.
IPO Year: 2014
Exchange: NASDAQ
Website: ardelyx.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/2/2024 | $15.00 → $7.00 | Overweight → Neutral | Piper Sandler |
4/5/2024 | $14.00 | Outperform | Leerink Partners |
12/18/2023 | $12.00 | Strong Buy | Raymond James |
9/7/2023 | $9.00 | Buy | H.C. Wainwright |
8/25/2023 | $5.00 → $10.00 | Neutral → Overweight | Cantor Fitzgerald |
3/3/2023 | $3.00 → $6.00 | Neutral → Outperform | Wedbush |
11/17/2022 | $3.00 → $8.00 | Neutral → Overweight | Piper Sandler |
5/6/2022 | $7.00 → $1.00 | Overweight → Neutral | Cantor Fitzgerald |
3/2/2022 | $1.00 → $5.00 | Hold → Buy | Jefferies |
12/1/2021 | $7.00 → $13.00 | Buy | Citigroup |
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
4 - ARDELYX, INC. (0001437402) (Issuer)
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
8-K - ARDELYX, INC. (0001437402) (Filer)
10-Q - ARDELYX, INC. (0001437402) (Filer)
8-K - ARDELYX, INC. (0001437402) (Filer)
144 - ARDELYX, INC. (0001437402) (Subject)
144 - ARDELYX, INC. (0001437402) (Subject)
8-K - ARDELYX, INC. (0001437402) (Filer)
144 - ARDELYX, INC. (0001437402) (Subject)
WALTHAM, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Justin Renz, Chief Financial and Operations Officer, will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 9:10 A.M. Eastern Time in New York City. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will
WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te
IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. "In the second quarter, Ardelyx demonstrated our commitment to our mission and to
WALTHAM, Mass., July 31, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the publication of plain language summaries of results from two clinical trials on XPHOZAH® (tenapanor), NORMALIZE and OPTIMIZE, in Current Medical Research and Opinion. The plain language summaries were developed by the authors to help adult patients with chronic kidney disease receiving dialysis, and their family members and caregivers, better understand some of the safety and efficacy data related to XPHOZAH. XPHOZAH, the fir
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the In
Lawsuit challenges CMS's statutory overreach in its determination to include oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System Inclusion of oral-only phosphate lowering therapies within the ESRD PPS limits patient choice and timely access to important innovations and treatment options for unmet needs WALTHAM, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in partnership with the American Association of Kidney Patients (AAKP), the
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH® (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) En
WALTHAM, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference, currently taking place in Nashville, Tennessee. Poster IND #37, entitled "Educational Needs Related to Irritable Bowel Syndrome with Constipation (IBS-C) Management Across Disciplines: a Compar
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company's board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company's common stock, and granted 13 new non-executive employees an aggregate of 179,050 Restricted Stock Units (RSUs). Each stock option has an exercise price equal to $7.44 per share, which was the closing trading price of the company's common stoc
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City. To access the live webcast of the panel presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations.
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
Submission status for ARDELYX INC's drug XPHOZAH (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug XPHOZA™ (ORIG-1) with active ingredient TENAPANOR has changed to 'Approval' on 10/17/2023. Application Category: NDA, Application Number: 213931, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-4) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 04/05/2022. Application Category: NDA, Application Number: 211801, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-3) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 05/19/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling
Submission status for ARDELYX INC's drug IBSRELA (SUPPL-2) with active ingredient TENAPANOR HYDROCHLORIDE has changed to 'Approval' on 03/05/2021. Application Category: NDA, Application Number: 211801, Application Classification: Labeling
Piper Sandler downgraded Ardelyx from Overweight to Neutral and set a new price target of $7.00 from $15.00 previously
Leerink Partners initiated coverage of Ardelyx with a rating of Outperform and set a new price target of $14.00
Raymond James initiated coverage of Ardelyx with a rating of Strong Buy and set a new price target of $12.00
H.C. Wainwright initiated coverage of Ardelyx with a rating of Buy and set a new price target of $9.00
Cantor Fitzgerald upgraded Ardelyx from Neutral to Overweight and set a new price target of $10.00 from $5.00 previously
Wedbush upgraded Ardelyx from Neutral to Outperform and set a new price target of $6.00 from $3.00 previously
Piper Sandler upgraded Ardelyx from Neutral to Overweight and set a new price target of $8.00 from $3.00 previously
Cantor Fitzgerald downgraded Ardelyx from Overweight to Neutral and set a new price target of $1.00 from $7.00 previously
Jefferies upgraded Ardelyx from Hold to Buy and set a new price target of $5.00 from $1.00 previously
Citigroup reiterated coverage of Ardelyx with a rating of Buy and set a new price target of $13.00 from $7.00 previously
WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Eric Foster as the company's Chief Commercial Officer. Mr. Foster is an experienced leader with more than 23 years of commercial experience for significant global biotech and pharmaceutical companies across numerous complex rare disease and specialty markets. Mr. Foster will be responsible for leading all commercial strategies for the company's two first-in-class medicines, IBSRELA® (tenapanor) and XPHOZAH® (te
WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy. Mr. Kelliher, an accomplished leader with more than 20 years of experience in the biopharmaceutical industry, brings to Ardelyx an extensive array of mergers and acquisitions, business development, strategy, finance and operational leadership expertise from leading biotechnology and global pharmaceutical companies.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced the appointment of Muna Bhanji, R.Ph., to its board of directors. "We welcome Muna whose deep expertise in global commercialization and market access will be critical to Intellia as we expand our leadership position in the field of genome editing and move closer to commercializing potentially curative treatments for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We are very fortunate to benef
FREMONT, Calif. and WALTHAM, Mass., March 15, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced the appointment of Muna Bhanji, R.Ph, to the company's board of directors, effective March 11, 2021. Ardelyx also announced that long time director, Gordon Ringold, Ph.D., stepped down from the board effective March 11, 2021. "We are thrilled to welcome Muna to our board of directors," said Mike Raab, president and chief executive officer of Ardelyx. "She is a veteran leader recognized for developing global strategies in drug
HC Wainwright & Co. analyst Ed Arce reiterates Ardelyx (NASDAQ:ARDX) with a Buy and maintains $10 price target.
Drugmaker Ardelyx Inc (NASDAQ:ARDX) has reportedly taken legal action against the U.S. Department of Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) regarding their decision to incorporate its kidney disease treatment drug, Xphozah, into the Medicare payment bundle system. The lawsuit contends that including Xphozah and other oral-only phosphate-lowering therapies in the End-Stage Renal Disease Prospective Payment System (ESRD PPS) will severely limit patient access and choice of crucial medications. Ardelyx argues that such medications, including Xphozah, are not administered during dialysis sessions and cannot feasibly be provided by dialysis facili
Wedbush analyst Laura Chico reiterates Ardelyx (NASDAQ:ARDX) with a Outperform and maintains $11 price target.
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $14 to $10.
Ardelyx, Inc. (NASDAQ:ARDX) shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) Transitional Drug Add-on Payment Adjustment. The Details: Ardelyx said its analysis of the CMS policy to include oral-only medicines in the PPS and the calendar year 2025 ESRD PPS Proposed Rule released on June 27, revealed that the policy and the manner in which CMS intends to implement it are likely to cause significant restrictions on the use of XPHOZAH for all patients because it interferes with the essential and appropriate shared decisio
Ardelyx's analysis of the CMS policy to include oral-only medicines in the PPS and the Calendar Year 2025 ESRD PPS Proposed Rule released on June 27, 2024, revealed that the policy and the manner in which CMS intends to implement it are likely to cause significant restrictions on the use of XPHOZAH for all patients, irrespective of insurance coverage, because it interferes with the essential and appropriate shared decision-making between healthcare professionals and their patients.
Analysts' ratings for Ardelyx (NASDAQ:ARDX) over the last quarter vary from bullish to bearish, as provided by 6 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 0 0 0 Last 30D 0 0 0 0 0 1M Ago 0 2 0 0 0 2M Ago 1 1 0 0 0 3M Ago 0 2 0 0 0 Analysts have set 12-month price targets for Ardelyx, revealing an average target of $14.5, a high estimate of $15.00, and a low estimate of $14.00. Marking an increase of 3.57%, the current average surpasses the previous average price
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
SC 13G - ARDELYX, INC. (0001437402) (Subject)
SC 13G/A - ARDELYX, INC. (0001437402) (Subject)
IBSRELA generates $35.4 million in net product sales revenue XPHOZAH generates $37.1 million in net product sales revenue Company ends Q2 with approximately $186 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2024 and provided a business update. "In the second quarter, Ardelyx demonstrated our commitment to our mission and to
WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, August 1, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the second quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the In
Ardelyx continues support for bipartisan legislation that would extend the exclusion of oral-only medications from entering the CMS Prospective Payment System Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that, in an effort to preserve patient access to its phosphate absorption inhibitor XPHOZAH® (tenapanor), the Company has chosen not to apply to include XPHOZAH in the Centers for Medicare & Medicaid Services (CMS) En
Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately $203 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2024 and provided a business update. "The first quarter of 2024 mar
WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Inves
Strong commercial performance of IBSRELA continues, ending FY 2023 with $80.1 million in net product sales revenue; 2024 net product sales revenue currently expected to be between $140.0 to $150.0 million XPHOZAH launch off to a strong start, ending FY 2023 with $2.5 million in net product sales revenue Company ends FY 2023 with $184.3 million in cash and investments Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial
WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2023 financial results and provide a business update. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under t
Continued successful launch of IBSRELA, with Q3 net sales revenue of $22.3 million; Company currently expects 2023 full year IBSRELA U.S. net sales revenue to be $76 to $78 million XPHOZAH® launch underway following October 17, 2023 FDA approval Company ends Q3 with $165.1 million in cash, cash equivalents and short-term investments Conference call scheduled for 8:00 AM Eastern Time WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results fo
WALTHAM, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Tuesday, October 31, 2023, at 8:00 a.m. Eastern Time to discuss third quarter financial results and provide a business update. To participate in the conference call, please dial (844) 481-2838 (domestic) or (412) 317-1858 (international) and ask to be joined into the Ardelyx call. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section o
WALTHAM, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that it has amended the debt financing agreement with investment affiliates managed by SLR Capital Partners (SLR) it originally entered into in February 2022. The amendment includes access to an additional $50 million in committed debt financing, at Ardelyx's election, and, subject to SLR credit approval, may be further increased by an additional $50 million. The interest-only period for existing and new tranches funded under the